Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing

Mucosal healing on endoscopy has emerged as a key prognostic parameter in the management of patients with IBD (Crohn’s disease, ulcerative colitis/UC) and can predict sustained clinical remission and resection-free survival. The structural basis for this type of mucosal healing is a progressive resolution of intestinal inflammation with associated healing of ulcers and improved epithelial barrier function. However, in some cases with mucosal healing on endoscopy, evidence of histological activity in mucosal biopsies has been observed. Subsequently, in UC, a second, deeper type of mucosal healing, denoted histological healing, was defined which requires the absence of active inflammation in mucosal biopsies. Both levels of mucosal healing should be considered as initial events in the resolution of gut inflammation in IBD rather than as indicators of complete transmural healing. In this review, the effects of anti-inflammatory, biological or immunosuppressive agents as well as small molecules on mucosal healing in clinical studies are highlighted. In addition, we focus on the implications of mucosal healing for clinical management of patients with IBD. Moreover, emerging techniques for the analysis of mucosal healing as well as potentially deeper levels of mucosal healing such as transmural healing and functional barrier healing of the mucosa are discussed. Although none of these new levels of healing indicate a definitive cure of the diseases, they make an important contribution to the assessment of patients’ prognosis. The ultimate level of healing in IBD would be a resolution of all aspects of intestinal and extraintestinal inflammation (complete healing).

[1]  N. Kapel,et al.  Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. , 2023, Clinical and translational gastroenterology.

[2]  G. D'Haens,et al.  Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. , 2023, The New England journal of medicine.

[3]  A. Shields,et al.  A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes Score, Robarts Histopathology Index, and Nancy Index. , 2023, Journal of Crohn's & colitis.

[4]  M. Grova,et al.  Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease. , 2023, Journal of gastroenterology and hepatology.

[5]  L. Peyrin-Biroulet,et al.  Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes , 2023, Journal of Crohn's & colitis.

[6]  E. Louis,et al.  In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab. , 2023, Inflammatory bowel diseases.

[7]  M. Silverberg,et al.  Vedolizumab for the Treatment of Chronic Pouchitis. , 2023, The New England journal of medicine.

[8]  E. Grisan,et al.  Artificial Intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. , 2023, Gastroenterology.

[9]  B. Sands,et al.  Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. , 2023, The lancet. Gastroenterology & hepatology.

[10]  B. Verstockt,et al.  Patient reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study. , 2023, Journal of Crohn's & colitis.

[11]  Minhu Chen,et al.  Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn’s disease receiving ustekinumab , 2023, Therapeutic advances in gastroenterology.

[12]  E. Peeva,et al.  Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. , 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  D. Rubin,et al.  Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is it Ready for Standard Practice? , 2023, Gastroenterology.

[14]  M. Byrne,et al.  Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems. , 2022, Journal of Crohn's & colitis.

[15]  Q. Lu,et al.  Trans-Compartmental Regulation of Tight Junction Barrier Function , 2022, Tissue barriers.

[16]  M. Neurath,et al.  Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in IBD: the prospective ERIca trial. , 2022, Gastroenterology.

[17]  S. Vermeire,et al.  Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. , 2022, The lancet. Gastroenterology & hepatology.

[18]  M. Regueiro,et al.  The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium , 2022, The American journal of gastroenterology.

[19]  M. Neurath,et al.  Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT score (ErLangen Endocytoscopy in ColiTis). , 2022, Gastrointestinal endoscopy.

[20]  B. Christensen Histologic Healing in Inflammatory Bowel Disease. , 2022, Gastroenterology & hepatology.

[21]  A. Bitton,et al.  Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis , 2022, The American journal of gastroenterology.

[22]  Kyeong Ok Kim Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice , 2022, Clinical endoscopy.

[23]  J. Marshall,et al.  The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. , 2022, Inflammatory bowel diseases.

[24]  Fraser Cummings,et al.  Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial , 2022, The Lancet.

[25]  Qiuhe Lu,et al.  Local barriers configure systemic communications between the host and microbiota , 2022, Science.

[26]  S. Ishihara,et al.  Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission. , 2022, Inflammatory bowel diseases.

[27]  S. Vermeire,et al.  Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis. , 2022, Journal of Crohn's & colitis.

[28]  M. Dubinsky,et al.  Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials , 2022, The Lancet.

[29]  M. Dubinsky,et al.  Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial , 2022, The Lancet.

[30]  S. Vermeire,et al.  Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials , 2022, The Lancet.

[31]  M. Neurath,et al.  Impact of Epithelial Cell Shedding on Intestinal Homeostasis , 2022, International journal of molecular sciences.

[32]  P. Gibson,et al.  Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease , 2022, Alimentary pharmacology & therapeutics.

[33]  G. Latella,et al.  Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis , 2022, BMC Gastroenterology.

[34]  M. Iacucci,et al.  Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?-Author's reply. , 2022, United European gastroenterology journal.

[35]  E. Grisan,et al.  PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system , 2022, Gut.

[36]  D. Rubin,et al.  Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. , 2022, Gastroenterology.

[37]  S. Vermeire,et al.  Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. , 2022, The lancet. Gastroenterology & hepatology.

[38]  G. Fiorino,et al.  Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art , 2022, Journal of clinical medicine.

[39]  G. Fiorino,et al.  Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives? , 2022, United European gastroenterology journal.

[40]  H. Yoon,et al.  Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse. , 2022, Inflammatory bowel diseases.

[41]  T. Grimstad,et al.  Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis , 2022, Therapeutic advances in gastroenterology.

[42]  J. Panés,et al.  The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12. , 2022, Gastroenterology & hepatology.

[43]  A. Ananthakrishnan,et al.  Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. , 2021, The lancet. Gastroenterology & hepatology.

[44]  P. Higgins,et al.  Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease. , 2021, Gastroenterology.

[45]  Teck Kiang Tan,et al.  Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. , 2021, The lancet. Gastroenterology & hepatology.

[46]  J. Garssen,et al.  Epithelial integrity, junctional complexes, and biomarkers associated with intestinal functions , 2021, Tissue barriers.

[47]  M. Dubinsky,et al.  Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement , 2021, Journal of Crohn's & colitis.

[48]  S. Hanauer,et al.  Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. , 2021, The New England journal of medicine.

[49]  M. Ferrante,et al.  Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication? , 2021, Inflammatory Intestinal Diseases.

[50]  A. Desideri,et al.  GATA6 deficiency leads to epithelial barrier dysfunction and enhances susceptibility to gut inflammation. , 2021, Journal of Crohn's & colitis.

[51]  Fachao Zhi,et al.  An IRF1-dependent pathway of TNFα-induced shedding in intestinal epithelial cells. , 2021, Journal of Crohn's & colitis.

[52]  M. Kamm,et al.  Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. , 2021, Inflammatory bowel diseases.

[53]  L. Peyrin-Biroulet,et al.  Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. , 2021, The lancet. Gastroenterology & hepatology.

[54]  S. Vermeire,et al.  Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial , 2021, The Lancet.

[55]  John A. Williams,et al.  Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission , 2021, Inflammatory bowel diseases.

[56]  T. Voiosu,et al.  Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review , 2021, World journal of gastroenterology.

[57]  H. Tilg,et al.  Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease , 2021, Journal of Crohn's & colitis.

[58]  J. Marshall,et al.  Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) , 2021, Gut.

[59]  M. Neurath,et al.  Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players , 2021, Frontiers in Medicine.

[60]  A. Saftoiu,et al.  Deep Learning Algorithm for the Confirmation of Mucosal Healing in Crohn's Disease, Based on Confocal Laser Endomicroscopy Images. , 2021, Journal of gastrointestinal and liver diseases : JGLD.

[61]  S. Vermeire,et al.  Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study , 2021, Journal of Crohn's & colitis.

[62]  C. Dai,et al.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2021, Visceral Medicine.

[63]  Qingli Zhu,et al.  Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn’s disease , 2021, Therapeutic advances in gastroenterology.

[64]  R. Kiesslich,et al.  An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in Ulcerative Colitis. , 2020, Gastroenterology.

[65]  L. Peyrin-Biroulet,et al.  Probe-based confocal laser endomicroscopy for in vivo assessment of histological healing in ulcerative colitis: development and validation of the ENHANCE index. , 2020, Journal of Crohn's & colitis.

[66]  T. Okumura,et al.  The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease , 2020, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[67]  A. Amiot,et al.  Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[68]  A. Variola,et al.  Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients′ Response to Biological Therapy and the Need for Colectomy , 2020, Digestion.

[69]  K. Tokushige,et al.  Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study , 2020, BMC Gastroenterology.

[70]  P. Dulai,et al.  Deep Learning Accurately Predicts Endoscopic and Histologic Remission in Ulcerative Colitis - What the Eye Doesn't See, the Artificial Mind Does Actually Know. , 2020, Gastroenterology.

[71]  A. Kornbluth Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right? , 2020, Inflammatory bowel diseases.

[72]  J. Lewis,et al.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. , 2020, Gastroenterology.

[73]  T. Hibi,et al.  Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. , 2020, Gastroenterology.

[74]  R. Bucala,et al.  CD74 Signaling Links Inflammation to Intestinal Epithelial Cell Regeneration and Promotes Mucosal Healing , 2020, Cellular and molecular gastroenterology and hepatology.

[75]  M. Silverberg,et al.  Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. , 2019, Inflammatory bowel diseases.

[76]  T. Kucharzik,et al.  Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study , 2019, Gut.

[77]  S. Vermeire,et al.  Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. , 2019, Gastroenterology.

[78]  P. Rutgeerts,et al.  Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn's Disease. , 2019, Gastroenterology.

[79]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[80]  B. Sands,et al.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.

[81]  Richard Strauss,et al.  A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials. , 2019, Journal of Crohn's & colitis.

[82]  B. Flourié,et al.  Usefulness of confocal laser endomicroscopy for predicting postoperative recurrence in patients with Crohn's disease: a pilot study. , 2019, Gastrointestinal endoscopy.

[83]  M. Neurath Targeting immune cell circuits and trafficking in inflammatory bowel disease , 2019, Nature Immunology.

[84]  Siddharth Singh,et al.  Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2019, The American journal of gastroenterology.

[85]  A. Ananthakrishnan,et al.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission , 2019, Alimentary pharmacology & therapeutics.

[86]  N. Caporaso,et al.  One‐year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing , 2019, Alimentary pharmacology & therapeutics.

[87]  N. Moreno,et al.  Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn’s Disease , 2019, Digestive Diseases and Sciences.

[88]  Emmanuel Coron,et al.  Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases. , 2019, Gastrointestinal endoscopy.

[89]  Tsuyoshi Ozawa,et al.  Novel computer-assisted diagnosis system for endoscopic disease activity in patients with ulcerative colitis. , 2019, Gastrointestinal endoscopy.

[90]  K. Mori,et al.  Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). , 2019, Gastrointestinal endoscopy.

[91]  A. Kaser,et al.  Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. , 2018, The lancet. Gastroenterology & hepatology.

[92]  P. Rutgeerts,et al.  Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. , 2018, Gastroenterology.

[93]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[94]  A. Griffiths,et al.  Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[95]  M. Neurath,et al.  I-scan optical enhancement for the in vivo prediction of diminutive colorectal polyp histology: Results from a prospective three-phased multicentre trial , 2018, Endoscopy.

[96]  R. Leong,et al.  Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases , 2018, Proteomes.

[97]  R. Kiesslich,et al.  Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps , 2018, Endoscopy.

[98]  M. Neurath,et al.  Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. , 2017, Gastrointestinal endoscopy.

[99]  B. Moum,et al.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis , 2017, Gastroenterology research and practice.

[100]  T. Phan,et al.  Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. , 2017, Gastroenterology.

[101]  P. Rutgeerts,et al.  Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis , 2017, Journal of Crohn's & colitis.

[102]  M. Neurath,et al.  Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[103]  B. Feagan,et al.  Histologic scoring indices for evaluation of disease activity in ulcerative colitis. , 2017, The Cochrane database of systematic reviews.

[104]  Chao Ding,et al.  Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis , 2017, Gastroenterology report.

[105]  Wolfgang Uter,et al.  Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity. , 2017, The New England journal of medicine.

[106]  M. Neurath,et al.  Mend Your Fences , 2017, Cellular and molecular gastroenterology and hepatology.

[107]  H. Ogata,et al.  Endocytoscopy can be used to assess histological healing in ulcerative colitis , 2017, Endoscopy.

[108]  R. Kiesslich,et al.  Advanced endoscopy imaging in inflammatory bowel diseases. , 2017, Gastrointestinal endoscopy.

[109]  L. Laine,et al.  Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis , 2016, The American Journal of Gastroenterology.

[110]  M. Dubinsky,et al.  Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis , 2016, Inflammatory bowel diseases.

[111]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, American Journal of Gastroenterology.

[112]  P. Higgins,et al.  Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis , 2016, Inflammatory bowel diseases.

[113]  M. Regueiro,et al.  Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. , 2016, Gastroenterology.

[114]  D. Morozov,et al.  A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease , 2016, Journal of pediatric gastroenterology and nutrition.

[115]  T. Matozaki,et al.  Promotion of Intestinal Epithelial Cell Turnover by Commensal Bacteria: Role of Short-Chain Fatty Acids , 2016, PloS one.

[116]  S. Vermeire,et al.  Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.

[117]  S. Osawa,et al.  The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. , 2016, Journal of Crohn's & colitis.

[118]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[119]  S. Travis,et al.  Development and validation of the Nancy histological index for UC , 2015, Gut.

[120]  D. Altman,et al.  The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS] , 2015, Journal of Crohn's & colitis.

[121]  P. Vilmann,et al.  Confocal laser endomicroscopy: a novel method for prediction of relapse in Crohn’s disease , 2015, Endoscopy.

[122]  J. Mansfield,et al.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.

[123]  B. Korelitz,et al.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. , 2014, World journal of gastroenterology.

[124]  P. Piselli,et al.  Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: a pilot study. , 2014, Journal of Crohn's & colitis.

[125]  Wolfgang Uter,et al.  In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.

[126]  I. Ordás,et al.  Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. , 2014, Gastroenterology.

[127]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[128]  A. Amiot,et al.  European evidence based consensus for endoscopy in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[129]  E. Louis,et al.  Serum calprotectin as a biomarker for Crohn's disease. , 2013, Journal of Crohn's & colitis.

[130]  H. Ogata,et al.  Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. , 2013, Journal of Crohn's & colitis.

[131]  D. Rubin,et al.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[132]  P. Rutgeerts,et al.  Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. , 2013, Gastroenterology.

[133]  M F Neurath,et al.  New targets for mucosal healing and therapy in inflammatory bowel diseases , 2013, Mucosal Immunology.

[134]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[135]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[136]  N. Caporaso,et al.  Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn’s Disease on Maintenance Treatment with Biologics , 2013, Inflammatory bowel diseases.

[137]  W. Sandborn,et al.  52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants , 2013, Inflammatory bowel diseases.

[138]  S. Travis,et al.  Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. , 2013, Journal of Crohn's & colitis.

[139]  M. Neurath,et al.  Endocytoscopy Allows Accurate In Vivo Differentiation of Mucosal Inflammatory Cells in IBD: A Pilot Study , 2013, Inflammatory bowel diseases.

[140]  A. Schoepfer,et al.  Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.

[141]  M. Neurath,et al.  Assessment of Crohn's disease activity by confocal laser endomicroscopy , 2012, Journal of Digestive Endoscopy.

[142]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[143]  M. Neurath,et al.  Mucosal healing in inflammatory bowel diseases: a systematic review , 2012, Gut.

[144]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[145]  T. Matsui,et al.  Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis , 2012, Inflammatory bowel diseases.

[146]  O. Dewit,et al.  Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol , 2012, Gut.

[147]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[148]  R. Kiesslich,et al.  Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease , 2011, Gut.

[149]  D. Altman,et al.  Translational Gastroenterology , 2011 .

[150]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[151]  J. Llach,et al.  Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. , 2011, Gastrointestinal endoscopy.

[152]  Helmut Neumann,et al.  Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis , 2011, Nature.

[153]  H. Ogata,et al.  Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis , 2011, Journal of Gastroenterology.

[154]  Helmut Neumann,et al.  Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBD. , 2011, Histology and histopathology.

[155]  V. de Lédinghen,et al.  Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab , 2011, Alimentary pharmacology & therapeutics.

[156]  Helmut Neumann,et al.  New endoscopic approaches in IBD. , 2011, World journal of gastroenterology.

[157]  I. Ordás,et al.  Colonic Crohn’s disease: value of magnetic resonance colonography for detection and quantification of disease activity , 2010, Abdominal Imaging.

[158]  M. Allez,et al.  Role of endoscopy in predicting the disease course in inflammatory bowel disease. , 2010, World journal of gastroenterology.

[159]  S. Gallus,et al.  Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study , 2010, The American Journal of Gastroenterology.

[160]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[161]  A. Sapino,et al.  Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. , 2010, Inflammation & allergy drug targets.

[162]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[163]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[164]  K. Petraki,et al.  Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid‐Dependent Crohn's Disease , 2009, Inflammatory bowel diseases.

[165]  K. Thakkar,et al.  Repeat Endoscopy Affects Patient Management in Pediatric Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[166]  I. Ordás,et al.  Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease , 2009, Gut.

[167]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[168]  N. Harpaz,et al.  Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial , 2008, The American Journal of Gastroenterology.

[169]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[170]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[171]  M. Kamm,et al.  MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials , 2007, Alimentary pharmacology & therapeutics.

[172]  P. Rutgeerts,et al.  Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? , 2007, Gut.

[173]  M. Bala,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .

[174]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[175]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[176]  T. Horiuchi,et al.  Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.

[177]  C. López-Otín,et al.  Differential Expression of Three Matrix Metalloproteinases, MMP-19, MMP-26, and MMP-28, in Normal and Inflamed Intestine and Colon Cancer , 2004, Digestive Diseases and Sciences.

[178]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[179]  A. Røseth,et al.  Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease , 2004, Scandinavian journal of gastroenterology.

[180]  Bernhard Nafe,et al.  Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. , 2003, Gastroenterology.

[181]  M. Neurath,et al.  Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies , 2002, American Journal of Gastroenterology.

[182]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[183]  R. Jian,et al.  Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy , 2002, American Journal of Gastroenterology.

[184]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[185]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[186]  V. Dessirier,et al.  Transforming Growth Factor-α and Epidermal Growth Factor Receptor in Colonic Mucosa in Active and Inactive Inflammatory Bowel Disease , 2000, Growth factors.

[187]  Å. Danielsson,et al.  Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.

[188]  T. Kardos,et al.  Comparison of cryosurgery and the carbon dioxide laser in mucosal healing. , 1991, International journal of oral and maxillofacial surgery.

[189]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[190]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[191]  M. Langer,et al.  [Effect of immediate dentures on mucosal healing and bone remodeling]. , 1984, L' Information dentaire.

[192]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[193]  W. Sandborn,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.

[194]  J. E. Domínguez-Muñoz,et al.  Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. , 2016, Journal of Crohn's & colitis.

[195]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[196]  A. Zinsmeister,et al.  Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[197]  L. Peyrin-Biroulet,et al.  Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.

[198]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[199]  A. Cohen,et al.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.

[200]  V. Dessirier,et al.  Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. , 2000, Growth factors.

[201]  D. Freeman,et al.  Early mucosal healing and chronic changes in pony jejunum after various types of strangulation obstruction. , 1988, American journal of veterinary research.

[202]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[203]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.